title: Relationship of anabolic status and phase and rate of growth to priorities for protein and fat deposition in steers.
abstract: The effects of anabolic implants, growth phase (growing vs finishing) and rate of growth on the priorities for protein and fat deposition were determined in yearling cattle. Santa Gertrudis crossbred yearling steers weighing 290 kg were individually fed diets varying in forage and grain content and either not implanted (n = 16) or implanted (90-d intervals) with Ralgro (n = 13) or Synovex-S (n = 12) implants. The cattle were fed toward a similar expected final empty BW (455 kg). Initial and interim empty body composition was measured via deuterium oxide dilution; final composition was determined by carcass specific gravity. During a 100-d growing phase, rates of protein gain were increased (P less than .12) to 118 and 131 g/d from 98 g/d for Ralgro and Synovex vs nonimplanted cattle, respectively. Concurrently, the fraction of protein in empty body growth was increased (P less than .09) from 17.5% for controls to 23.8 and 19.7% for Ralgro- and Synovex-implanted steers, respectively. This change in protein growth occurred concomitant with mobilization of fat and a reduction (P less than .04) in fat gain with Ralgro and Synovex implants. During the 136-d finishing phase, protein accretion was 115 and 132 vs 93 g/d for Ralgro- and Synovex-implanted cattle vs nonimplanted cattle; this represented a 24 and 42% increase (P less than .03) with Ralgro and Synovex, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Texas A&M Univ., College Station 77843.
authors.forename: P G
authors.initials: PG
authors.lastname: Lemieux
authors.forename: F M
authors.initials: FM
authors.lastname: Byers
authors.forename: G T
authors.initials: GT
authors.lastname: Schelling
mesh_terms: D000273:Adipose Tissue / Q000378:metabolism; D045930:Anabolic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D000818:Animals; D001823:Body Composition; D002417:Cattle / Q000254:growth & development / Q000378:metabolism*; D004338:Drug Combinations / Q000008:administration & dosage / Q000494:pharmacology; D004343:Drug Implants; D004958:Estradiol / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000494:pharmacology; D050356:Lipid Metabolism; D008297:Male; D011374:Progesterone / Q000008:administration & dosage / Q000494:pharmacology; D011506:Proteins / Q000378:metabolism*; D011897:Random Allocation; D012044:Regression Analysis; D015430:Weight Gain; D015029:Zeranol / Q000008:administration & dosage / Q000494:pharmacology
chemical_list: D045930:Anabolic Agents; D004338:Drug Combinations; D004343:Drug Implants; D011506:Proteins; D011374:Progesterone; D004958:Estradiol; D015029:Zeranol; C025370:estradiol benzoate, progesterone drug combination